ACAM 529

Drug Profile

ACAM 529

Alternative Names: ACAM529; dl5-29 HSV-2 vaccine - Acambis; Herpes vaccine - Harvard Medical School/Acambis; HSV-529

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator Harvard Medical School
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi Pasteur
  • Class Antivirals; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Herpes simplex virus infections

Most Recent Events

  • 01 Nov 2015 Fred Hutchinson Cancer Research Center initiates a phase I trial for Herpes simplex virus infections in USA (Parenteral) (NCT02571166)
  • 16 Oct 2014 Sanofi Pasteur and Immune Design Corporation enter into a broad collaboration to develop HSV immunotherapy
  • 31 Jul 2013 Phase-I clinical trials in Herpes simplex virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top